Barclays’s Agios Pharmaceuticals AGIO Stock Holding History

Barclays’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-30,000	Closed	-$877K	–	4830
2024 Q1	$877K	Sell	30,000 -30,000	-50%	-$803K	﹤0.01%	3223
2023 Q4	$1.34M	Buy	+60,000	New	+$1.34M	﹤0.01%	3227
2018 Q3	–	Sell	-27,000	Closed	-$2.27M	–	7086
2018 Q2	$2.27M	Hold	27,000	–	–	﹤0.01%	2466
2018 Q1	$2.21M	Buy	+27,000	New	+$2.09M	﹤0.01%	2367
2016 Q4	–	Sell	-358,400	Closed	-$18.9M	–	6577
2016 Q3	$18.9M	Buy	+358,400	New	+$15.6M	0.02%	573

Other funds holding AGIO

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return

Barclays's AGIO Position: Q3 2026 in Review

Barclays increased its Agios Pharmaceuticals (AGIO) stake by 22% in Q3 2026, buying an estimated $372K and bringing the position to 58,936 shares worth $1.96M. The position accounts for ﹤0.01% of the portfolio, ranked #2608.

Barclays first reported a position in AGIO in Q3 2013 and has held it in 53 quarters since. The position peaked at $8.72M in Q4 2025. 85 funds tracked by Wall St. Rank hold AGIO as of Q3 2026.

Barclays held 58,936 shares of Agios Pharmaceuticals worth $1.96M as of Q3 2026.
Barclays bought 10,636 Agios Pharmaceuticals shares in Q3 2026, an estimated $372K.
Agios Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2608 holding.
Barclays first reported a position in Agios Pharmaceuticals in Q3 2013 and has held it in 53 quarters since.
Barclays's Agios Pharmaceuticals position peaked at $8.72M in Q4 2025.
85 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.